IDEC blog

  • To IDEC website top page
  • 2023.03.13

Announcement of 2023 Drug Price Revision in Japan

The 2023 revision of drug prices in Japan has been announced,

続きを読む

  • 2023.03.13

The 3rd PD-1 Inhibitor, LIBTAYO, approved in Japan

Sanofi’s LIBTAYO, Cemiplimab IV, was approved in December 2022

続きを読む

  • 2023.03.13

HAE Product, BERINERT SC, Listed in NHI Pricing List

CSL Behring’s BERINERT SC was approved for prevention of acute hereditary angioedema attacks, HAE, in September 2022.

続きを読む

Recent Posts

  • Announcement of 2023 Drug Price Revision in Japan
  • The 3rd PD-1 Inhibitor, LIBTAYO, approved in Japan
  • HAE Product, BERINERT SC, Listed in NHI Pricing List

Archive

  • March 2023

Category

  • Uncategorized
Idec Logo Reverse

Shinjuku i-Land Tower 41F
6-5-1 Nishi Shinjuku
Shinjuku-ku 163-1341
Tokyo, Japan

Tel: +81-3-6304-5570
Fax: +81-3-6304-5580

Contact Us

Follow Us on LinkedIn

© Copyright 2023 IDEC, Inc. All rights reserved.